MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SKYE had -$5,397,165 decrease in cash & cash equivalents over the period. -$13,364,375 in free cash flow.

Cash Flow Overview

Change in Cash
-$5,397,165
Free Cash flow
-$13,364,375

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss
-12,754,660 -28,728,191
Depreciation and amortization
178,898 364,445
Stock-based compensation expense
1,914,136 4,235,018
Amortization of debt discount
0 0
Gains from asset sales
91,400 89,363
Write-down of vendor deposits
0 0
Loss from disposal of assets
0 0
Change in estimate for legal contingency
0 -
Prepaid expenses
2,448,499 1,061,850
Other current assets
166,752 -1,476,121
Other assets
0 -
Accounts payable
-397,505 2,584,507
Accrued interest - legal contingency-Related Party
0 0
Accrued interest - legal contingency-Nonrelated Party
0 0
Accrued payroll liabilities
52,750 -246,231
Operating lease liability
-45,695 -88,050
Other current liabilities
394,352 1,621,927
Net cash used in operating activities
-13,364,375 -19,931,667
Proceeds from the sale of assets, net of sales costs
91,400 89,363
Purchase of short-term investments, net of maturities
-7,875,810 24,747,039
Purchase of property and equipment
0 6,312
Net cash used in investing activities
7,967,210 -24,663,988
Purchase under employee stock purchase plan
0 18,158
Proceeds from the issuance of common stock and warrants, net of equity issuance costs of 0 and 6,434,447, respectively
0 0
Net cash provided by financing activities
0 18,158
Net (decrease) increase in cash, cash equivalents and restricted cash
-5,397,165 -44,577,497
Cash and cash equivalents at beginning of period
68,415,741 -
Cash and cash equivalents at end of period
18,441,079 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Skye Bioscience, Inc. (SKYE)

Skye Bioscience, Inc. (SKYE)